Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;26(6):321-333.
doi: 10.1007/s12471-018-1113-5.

Optimal duration of dual antiplatelet therapy for coronary artery disease

W J Kikkert  1 , P Damman  2
Affiliations
Review

Optimal duration of dual antiplatelet therapy for coronary artery disease

W J Kikkert et al. Neth Heart J. 2018 Jun.

Abstract

The optimal duration of dual antiplatelet therapy (DAPT) for stable coronary artery disease and acute coronary syndrome is a complex decision. We review current literature on standard duration DAPT versus short duration DAPT (6 months or shorter) or extended duration DAPT (>12 months) after percutaneous coronary intervention with drug-eluting stent placement, and prolonged treatment after 12 months in acute coronary syndrome. Current guideline recommendations are summarised, including the use of risk scores for ischaemic and bleeding risk assessment. Because of the limitations of current risk scores, we propose multiple patient-related and procedure-related factors for the ischaemic and bleeding risk assessment aiding in personalised DAPT duration.

Keywords: DAPT; Long-term; Short-term.

PubMed Disclaimer

Conflict of interest statement

W.J. Kikkert reports receiving speaker fees from Astra Zeneca and P. Damman reports receiving a research grant from AstraZeneca.

Figures

Fig. 1
Fig. 1
a Flowchart illustrating the recommended duration of dual antiplatelet therapy in patients with stable coronary artery disease according to clinical and procedural risk factors for bleeding and ischaemia. b Flowchart illustrating recommended duration of dual antiplatelet therapy in patients with acute coronary syndrome (1In patients with an extremely high bleeding risk, such as those scheduled for non-deferrable surgery with high bleeding risk, a minimum of one month of DAPT is mandatory. ACS acute coronary syndrome, DM diabetes mellitus, DAPT dual antiplatelet therapy, NSTEMI non-ST-segment elevation myocardial infarction, PCI percutaneous coronary intervention, SAPT single antiplatelet therapy, SCAD stable coronary disease, STEMI ST-segment elevation myocardial infarction)
None
See this image and copyright information in PMC

References

    1. Population Division. Department of Economic and Social Affairs. United Nations. Revision of World Population Prospects. https://esa.un.org/unpd/wpp/. Accessed 13.10.2017
    1. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676–1688. doi: 10.1161/01.CIR.91.6.1676. - DOI - PubMed
    1. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519–1521. doi: 10.1016/S0140-6736(04)17275-9. - DOI - PubMed
    1. Dangas GD, Serruys PW, Kereiakes DJ, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3‑year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) JACC Cardiovasc. Interv. 2013;6:914–922. doi: 10.1016/j.jcin.2013.05.005. - DOI - PubMed
    1. Kikkert WJ, Hoebers LP, Damman P, et al. Recurrent myocardial infarction after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol. 2014;113:229–235. doi: 10.1016/j.amjcard.2013.08.039. - DOI - PubMed

LinkOut - more resources